The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CytomX Therapeutics Inc shares valued at $5,139 were sold by Landau Jeffrey B on Aug 20 ’24. At $1.23 per share, Landau Jeffrey B sold 4,181 shares. The insider’s holdings dropped to 119,056 shares worth approximately $0.13 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, BELVIN MARCIA sold 4,181 shares, netting a total of over 5,139 in proceeds. Following the sale of shares at $1.23 each, the insider now holds 175,648 shares.
Before that, ROWLAND LLOYD A had sold 4,181 shares from its account. In a trade valued at $5,139, the General Counsel traded CytomX Therapeutics Inc shares for $1.23 each. Upon closing the transaction, the insider’s holdings decreased to 4,181 shares, worth approximately $0.15 million.
As published in a research note from Piper Sandler on May 28, 2024, CytomX Therapeutics Inc [CTMX] has been rated up from a Neutral to an Overweight and the price target has been revised to $3.50 from $2.25. Analysts at Wedbush upgraded the stock from ‘”a Neutral”‘ to ‘”an Outperform”‘ outlook in a report released in early May. As of May 06, 2024, Jefferies has increased its “Hold” rating to a “Buy” for CTMX. Earlier on April 22, 2024, JP Morgan upgraded its rating. Their new recommendation was “a Neutral” for CTMX stock which previously was a “an Underweight”.
Analyzing CTMX Stock Performance
During the last five days, there has been a drop of approximately -0.88%. Over the course of the year, CytomX Therapeutics Inc shares have dropped approximately -27.74%. Shares of the company reached a 52-week high of $5.8500 on 05/01/24 and a 52-week low of $1.0900 on 09/04/24. A 50-day SMA is recorded $1.1988, while a 200-day SMA reached $1.6728. Nevertheless, trading volume fell to 0.84 million shares from 0.41 million shares the previous day.
Support And Resistance Levels for CytomX Therapeutics Inc (CTMX)
According to the 24-hour chart, there is a support level at 1.1033, which, if violated, would cause prices to drop to 1.0867. In the upper region, resistance lies at 1.1483. The next price resistance is at 1.1767. RSI (Relative Strength Index) is 40.65 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0240, which suggests the price will decrease in the coming days. Percent R is at 89.29%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
